🏛️ Verified NIH Record • Updated 2026-07-07
Visual Remapping to Aid Reading With Field Loss (NCT03848663)
Remapping the Visual Field to Aid Reading With Central Scotomas
🟢 Recruiting Observational / Diagnostic 🧠 Behavioral & Psychological Program Sponsor: University of Minnesota
🩺 Plain-English Summary (8th-Grade Level)
Reading performance in patients with Central Vision Loss and age matched controls with artificial scotomas will be measured with and without different kinds of remapping of missing text to different parts of the visual field.
Who can join: Review the eligibility criteria below.
Location: University of Minnesota — Minneapolis, Minnesota
Age range: 16 Years
🧪 Interventions in This Study
- Traditional Remapping (BEHAVIORAL)
- Personalized Remapping (BEHAVIORAL)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- University of Minnesota — Minneapolis, Minnesota
📞 Contact the Study Coordinator
Phone: (612) 625-5571
Email: engel@umn.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Age-related Macular Degeneration
- A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus Pre-filled Syringe in Subjects With Visual Impairment Due to Retinal Disorders — Springfield, Illinois
- Safety and Efficacy Study of OpRegen for Treatment of Advanced Dry-Form Age-Related Macular Degeneration — San Francisco, California
- ForeseeHome NRich Registry — Toms River, New Jersey
- Impact of Non-Exudative Type 1 MNV on AMD Progression — Salt Lake City, Utah
- A Phase I, Open-label, Multicenter, Dose-Escalating Study to Evaluate the Safety and Tolerability of KH658 Gene Therapy in Participants With Neovascular Age-related Macular Degeneration — Phoenix, Arizona
- Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration — Scottsdale, Arizona
Explore by condition: All Age-related Macular Degeneration clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.